We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Dermatology

Journal Scan / Research · November 10, 2016

GP2015 Comparable With Etanercept Originator in Efficacy and Safety in Chronic Plaque-Type Psoriasis

The British Journal of Dermatology


Additional Info

The British Journal of Dermatology
The EGALITY Study: A Confirmatory, Randomised, Double-Blind Study Comparing the Efficacy, Safety and Immunogenicity of GP2015, a Proposed Etanercept Biosimilar, Versus the Originator Product in Patients With Moderate to Severe Chronic Plaque-Type Psoriasis
Br J Dermatol 2016 Oct 27;[EPub Ahead of Print], CE Griffiths, D Thaçi, S Gerdes, P Arenberger, G Pulka, K Kingo, J Weglowska, , N Hattebuhr, J Poetzl, H Woehling, G Wuerth, M Afonso

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading